Refine
Year of publication
Document Type
- Conference Proceeding (71)
- Article (reviewed) (15)
- Patent (11)
- Contribution to a Periodical (8)
- Article (unreviewed) (2)
Conference Type
- Konferenz-Abstract (55)
- Konferenzartikel (12)
- Konferenz-Poster (4)
Language
- English (80)
- German (25)
- Other language (1)
- Multiple languages (1)
Is part of the Bibliography
- yes (107)
Keywords
- CST (7)
- HF-Ablation (7)
- CRT (6)
- Herzrhythmusmodell (6)
- Heart rhythm model (5)
- Herzkrankheit (5)
- Modeling and simulation (5)
- Kardiale Resynchronisationstherapie (4)
- Synchronisierung (4)
- heart rhythm model (4)
Institute
- Fakultät Elektrotechnik und Informationstechnik (E+I) (bis 03/2019) (76)
- Fakultät Elektrotechnik, Medizintechnik und Informatik (EMI) (ab 04/2019) (28)
- POIM - Peter Osypka Institute of Medical Engineering (12)
- CRT - Campus Research & Transfer (2)
- Zentrale Einrichtungen (2)
- Fakultät Maschinenbau und Verfahrenstechnik (M+V) (1)
Open Access
- Open Access (70)
- Closed Access (29)
- Bronze (4)
- Closed (2)
About 20% of those heart failure patients receiving cardiac resynchronization therapy (CRT) are in atrial fibrillation (AF). Current guidelines apply for patients in sinus rhythm only. Recent studies have shown again, that successful resynchronization is closely linked to a pre-existent ventricular desynchronization. In those studies, the interventricular conduction delay (IVCD) was determined prior to device implantation by ultrasound in patients with sinus rhythm (SR)only. In patients with AF this method ́s use is limited.
To implement left-heart electrogram (LHE) into standard programmers and to simplify IVCD measurement in heart failure patients with AF, LHE was recorded in 11 AF patients with heart failure by Biotronik ICS3000 programmer via a15Hz Butterworth high-pass filter. Therefore, TOslim esophageal electrode (Dr. Osypka GmbH, Rheinfelden, Germany) was perorally applied and fixed in position of maximal left ventricular defection. IVCD was measured between onset of QRS in surface ECG and left ventricular defection (LV) in LHE. In addition, intra-left ventricular conduction delay (ILVCD) was measured as duration of LV in LHE.
In all of the 11 AF patients, desynchronization was quantifiable by LHE. Mean QRS of 162 ± 27ms (120-206ms) was linked with IVCD of 62ms ± 27ms (37-98ms) and ILVCD of 110 ± 20ms (80-144ms), at mean. Correlation between IVCD and QRS was 0.39 (n. s.) with IVCD/QRS ratio of 0.38 ± 0.11 (0.22-0.81).
A 15Hz high-pass filtered LHE feature of the Biotronik ICS3000 programmer is feasible to quantify ventricular dyssynchrony in heart failure patients with AF in order to clearly indicate implantation of CRT systems. As relations between QRS duration, IVCD and ILVCD considerably differ interindividually, the predictive values of IVCD, ILVCD and IVCD/QRS ratio for individual CRT response or non-response shall be identified in follow-up studies.
Cardiac resynchronization therapy (CRT) with biventricular pacing is an established therapy for heart failure (HF) patients (P) with ventricular desynchronization and reduced left ventricular (LV) ejection fraction. The aim of this study was to evaluate electrical right atrial (RA), left atrial (LA), right ventricular (RV) and LV conduction delay with novel telemetric signal averaging electrocardiography (SAECG) in implantable cardioverter defibrillator (ICD) P to better select P for CRT and to improve hemodynamics in cardiac pacing.
Methods: ICD-P (n=8, age 70.8 ± 9.0 years; 2 females, 6 males) with VVI-ICD (n=4), DDD-ICD (n=3) and CRT-ICD (n=1) (Medtronic, Inc., Minneapolis, MN, USA) were analysed with telemetric ECG recording by Medronic programmer 2090, ECG cable 2090AB, PCSU1000 oscilloscope with Pc-Lab2000 software (Velleman®) and novel National Intruments LabView SAECG software.
Results: Electrical RA conduction delay (RACD) was measured between onset and offset of RA deflection in the RAECG. Interatrial conduction delay (IACD) was measured between onset of RA deflection and onset of far-field LA deflection in the RAECG. Interventricular conduction delay (IVCD) was measured between onset of RV deflection in the RVECG and onset of LV deflection in the LVECG. Telemetric SAECG recording was possible in all ICD-P with a mean of 11.7 ± 4.4 SAECG heart beats, 97.6 ± 33.7 ms QRS duration, 81.5 ± 44.6 ms RACD, 62.8 ± 28.4 ms RV conduction delay, 143.7 ± 71.4 ms right cardiac AV delay, 41.5 ms LA conduction delay, 101.6 ms LV conduction delay, 176.8 ms left cardiac AV delay, 53.6 ms IACD and 93 ms IVCD.
Conclusions: Determination of RA, LA, RV and LV conduction delay, IACD, IVCD, right and left cardiac AV delay by telemetric SAECG recording using LabView SAECG technique may be useful parameters of atrial and ventricular desynchronization to improve P selection for CRT and hemodynamics in cardiac pacing.
Cardiac resynchronisation therapy (CRT) is a promising treatment option in patients with chronic heart failure. In this article the roles of semi-invasive esophageal left-heart electrocardiography and functional cardiac nuclear imaging in the field of CRT are highlighted, as the combination of both could be a favourable diagnostic approach in special cardiac situations. Also original esophageal left heart electrogram data of exemplary CRT patients is presented.
Oesophageal Electrode Probe and Device for Cardiological Treatment and/or Diagnosis (EP3706626A1)
(2020)
The invention relates to an oesophageal electrode probe (10) for bioimpedance measurement and/or for neurostimulation; a device (100) for transoesophageal cardiological treatment and/or cardiological diagnosis; and a method for the open-loop or closed-loop control of a cardiac catheter ablation device and/or a cardiac, circulatory and/or respiratory support device. The oesophageal electrode probe comprises a bioimpedance measuring device for measuring the bioimpedance of at least one part of the tissue surrounding the oesophageal electrode probe. The bioimpedance device comprises at least one first and one second electrode, wherein the at least one first electrode (12A) is arranged on a side (14) of the oesophageal electrode probe facing towards the heart and the at least one second electrode (12B) is arranged on a side (16) of the oesophageal electrode probe facing away from the heart. The device (100) comprises the oesophageal electrode probe (10) and a control and/or evaluation device (30), which is configured for receiving a first bioimpedance measurement signal from the at least one first electrode (12A) and a second bioimpedance measurement signal from the at least one second electrode (12B), and comparing same, and generating a control signal on the basis of the comparison. The control signal can be a signal for the open-loop or closed-loop control of a cardiac catheter ablation device and/or a cardiac, circulatory and/or respiratory support device.
Oesophageal Electrode Probe and Device for Cardiological Treatment and/or Diagnosis (US20200261024)
(2020)
An oesophageal electrode probe for bioimpedance measurement and/or for neurostimulation is provided; a device for transoesophageal cardiological treatment and/or cardiological diagnosis is also provided; a method for the open-loop or closed-loop control of a cardiological catheter ablation device and/or a cardiological, circulatory and/or respiratory support device is also provided. The oesophageal electrode probe comprises a bioimpedance measuring device for measuring the bioimpedance of at least one part of tissue surrounding the oesophageal electrode probe. The bioimpedance device comprises at least one first and one second electrode. The at least one first electrode is arranged on a side of the oesophageal electrode probe facing towards the heart. The at least one second electrode is arranged on a side of the oesophageal electrode probe facing away from the heart. The device comprises the oesophageal electrode probe and a control and/or evaluation device.
The invention relates to an oesophageal electrode probe (10) for bioimpedance measurement and/or for neurostimulation; a device (100) for transoesophageal cardiological treatment and/or cardiological diagnosis; and a method for the open-loop or closed-loop control of a cardiac catheter ablation device and/or a cardiac, circulatory and/or respiratory support device. The oesophageal electrode probe comprises a bioimpedance measuring device for measuring the bioimpedance of at least one part of the tissue surrounding the oesophageal electrode probe. The bioimpedance device comprises at least one first and one second electrode, wherein the at least one first electrode (12A) is arranged on a side (14) of the oesophageal electrode probe facing towards the heart and the at least one second electrode (12B) is arranged on a side (16) of the oesophageal electrode probe facing away from the heart. The device (100) comprises the oesophageal electrode probe (10) and a control and/or evaluation device (30), which is configured for receiving a first bioimpedance measurement signal from the at least one first electrode (12A) and a second bioimpedance measurement signal from the at least one second electrode (12B), and comparing same, and generating a control signal on the basis of the comparison. The control signal can be a signal for the open-loop or closed-loop control of a cardiac catheter ablation device and/or a cardiac, circulatory and/or respiratory support device.
Cardiac resynchronization therapy with atrioventricular and interventricular pacing delay optimized biventricular pacing is an established therapy for heart failure patients with sinus rhythm and reduced left ventricular ejection fraction. The aim of the study was to evaluate atrioventricular and interventricular pacing delay optimization in cardiac resynchroniza-tion therapy by transthoracic impedance cardiography in biventricular pacing with different left ventricular electrode po-sition. In biventricular pacing heart failure patients with lateral, posterolateral and anterolateral left ventricular electrode position, the mean optimal atrioventricular sening delay was 108.6 ± 20.3 ms and the mean optimal interventricular pac-ing delay -12.3 ± 25.9 ms. Transthoracic impedance cardiography may be a useful technique to optimize atrioventricular and interventricular pacing delay in biventricular pacing with different left ventricular electrode position.
In contrast to conventional aortic valve replacement, the Transcatheter Aortic Valve Implantation (TAVI) is a new highly specialist alternative to surgical valve replacement for patients with symptomatic severe aortic stenosis and high operative risk. The procedure was performed in a minimally invasive way and was introduced at the university heart centre, Freiburg – Bad Krozingen in 2008. The results have been getting better and better over the years. The aim of the investigation is the analysis of electrocardiogram conduction time and the electrocardiography changes recorded hours and days after the procedure depending on artificial heart valve models, which may lead to pacemaker implantation, even the analysis of the effectiveness of treatment.
Cardiac contractility modulation (CCM) is a device-based therapy for the treatment of systolic left ventricular chronic heart failure. Unlike other device-based therapies for heart failure, CCM delivers non-excitatory pacing signals to the myocardium. This leads to an extension of the action potential and to an improved contractility of the heart. The modeling and simulation was done with the electromagnetic simulation software CST. Three CCM electrodes were inserted into the Offenburg heart rhythm model and subsequently simulated the electric field propagation in CCM therapy.
In addition, simulations of CCM have been performed with electrodes from other device-based therapies, such as cardiac resynchronization therapy (CRT) and implantable cardioverter / defibrillator (ICD) therapy. At the same distance to the simulation electrode, the electric field is slightly stronger in CCM therapy than in CCM therapy with additionally implanted CRT or ICD electrodes. In addition, there is a change in the electric field propagation at the electrodes of the CRT and the shock electrode of the ICD.
By simulating several different therapy procedures on the heart, it is possible to check how they affect their behavior during normal operation. CCM heart rhythm model simulation allows the evaluation the individual electrical pacing and sensing field during CCM.
AV delay (AVD) optimization is mandatory in cardiac resynchronization (CRT) for heart failure. Several time consuming methods exist. We initialized development of left-atrial electrogram (LAE) feature for Biotronik ICS3000 programmer. It can be utilized to approximate optimal AV delay in CRT patients with pacing systems irrespective of make and model. Using this feature, we studied the share of interatrial conduction intervals (IACT) on individual echo AVD in 45 CRT patients (34m, 11f, mean age 69±6yrs.). The percentage of IACT on optimal echo AVD resulted in44.5±22.1% for VDD and 70.7±10.9% for DDD operation. In all patients, optimal echo AVDs exceeded the individual IACT by a duration of 52.5±33.3ms (p<0.001), at mean. Therefore, if AV delay optimization is not possible or not practicable in CRT patients, AVD should be approximated by individually measuring IACT and adding about 50ms.
Introduction: Patient selection for cardiac resynchronization therapy (CRT) requires quantification of left ventricular conduction delay (LVCD). After implantation of biventricular pacing systems, individual AV delay (AVD) programming is essential to ensure hemodynamic response. To exclude adverse effects, AVD should exceed individual implant-related interatrial conduction times (IACT). As result of a pilot study, we proposed the development of a programmer-based transoesophageal left heart electrogram (LHE) recording to simplify both, LVCD and IACT measurement. This feature was implemented into the Biotronik ICS3000 programmer simultaneously with 3-channel surface ECG.
Methods: A 5F oesophageal electrode was perorally applied in 44 heart failure CRT-D patients (34m, 10f, 65±8 yrs., QRS=162±21ms). In position of maximum left ventricular deflection, oesophageal LVCD was measured between onsets of QRS in surface ECG and oesophageal left ventricular deflection. Then, in position of maximum left atrial deflection (LA), IACT in VDD operation (As-LA) was calculated by difference between programmed AV delay and the measured interval from onset of left atrial deflection to ventricular stimulus in the oesophageal electrogram. IACT in DDD operation (Ap-LA) was measured between atrial stimulus and LA..
Results: LVCD of the CRT patients was characterized by a minimum of 47ms with mean of 69±23ms. As-LA and Ap-LA were found to be 41±23ms and 125±25ms, resp., at mean. In 7 patients (15,9%), IACT measurement in DDD operation uncovered adverse AVD if left in factory settings. In this cases, Ap-LA exceeded the factory AVD. In 6 patients (13,6%), IACT in VDD operation was less than or equal 10ms indicating the need for short AVD.
Conclusion: Response to CRT requires distinct LVCD and AVD optimization. The ICS3000 oesophageal LHE feature can be utilized to measure LVCD in order to justify selection for CRT. IACT measurement simplifies AV delay optimization in patients with CRT systems irrespective of their make and model.
Transcatheter aortic valve implantation is a therapy for patients with reduced left ventricular ejection fraction and symptomatic aortic stenosis. The aim of the study was to compare the pre-and post- transcatheter aortic valve implantation procedures to determine the QRS and QT ventricular conduction times as a potential predictor of permanent pacemaker therapy requirement after transcatheter aortic valve implantation. QRS and QT ventricular conduction times were prolonged after transcatheter aortic valve implantation in heart failure patients with permanent dual chamber pacemaker therapy after transcatheter aortic valve implantation. QRS and QT ventricular conduction times may be useful parameters to evaluate the risk of post-procedural ventricular conduction block and permanent pacemaker therapy in transcatheter aortic valve implantation.
Using guideline parameters for indication of cardiac resynchronization therapy (CRT), only about two thirds of the patients improve clinically. Unfortunately both, surface ECG and echo are uncertain to predict CRT response. To better characterize cardiac desynchronization in heart failure, interventricular (IVCD) and intra-leftventricular conduction delays (ILVCD) were measured by esophageal left ventricular electrogram (LVE). Recordings in 43 CRT patients (34m, 9f, age: 64.7 ± 9.5yrs) evidenced only weak correlation between IVCD and QRS of 0.53 and between ILVCD and QRS of 0.33. This demonstrated that QRS duration is not a reliable indicator of desynchronization. Therefore, the study resulted into development of LVE feature for a programmer with implant support device. It can be used interoperatively to guide the left ventricular electrode location in order to increase responder rate in CRT.
Semi-invasive electromechanical target interval to guide left ventricular electrode placement
(2011)
Introduction: Cardiac resynchronization therapy (CRT) with left ventricular (LV) pacing is an established therapy for heart failure (HF) patients (P) with ventricular desynchronisation and reduced LV ejection fraction (EF). The aim of this study was to test the utilization of the transesophageal approach to measure arterial pulse pressure (PP) during LV pacing and electrical interventricular conduction delay (IVCD), to better select patients for CRT.
Methods: 32 HF patients (age 64 ± 10 years; 5 females, 27 males) with New York Heart Association (NYHA) class 2.8 ± 0.6, 27 ± 11 % LV EF and 155 ± 35 ms QRS duration were analysed with semi-invasive left cardiac pacing and electrocardiography. Esophageal TO8 Osypka catheter of 10.5 F diameter was perorally applied to the esophagus and placed in the position of maximum left atrial (LA) deflection and maximum LV deflection to measure PP with VAT or D00 pacing modes.
Results: Temporary transesophageal LV pacing was possible with VAT mode (n=16) and D00 mode (n=16) in all patients. In 15 Δ-PP-responders, PP was higher during LV pacing on than LV pacing off (78.3 ± 26.6 versus 65.9 ± 23.7 mmHg, P < 0.001) and NYHA class improved from 3.1 ± 0.35 to 2.1 ± 0.35 (P < 0.001) during 29 ± 26 month biventricular (BV) pacing follow-up (6 Medtronic and 9 Boston BV pacing devices). In 17 Δ-PP-non-responders, PP was not higher during LV pacing on than LV pacing off (61.5 ± 23.9 versus 60.9 ± 23.5 mmHg, P = 0.066). IVCD was significant longer in Δ-PP-responders than in Δ-PP-non-responders (87 ± 33 ms versus 37± 29 ms, P < 0.001).
Conclusion: Semi-invasive transesophageale LA and LV pacing with D00 and VAT mode and LV electrogram recording may be useful techniques to predict CRT improvement.